Efficacy of Nortriptyline and Migraine Lifestyle Modifications in Vestibular Migraine Management.
diet
lifestyle
migraine
nortriptyline
vestibular migraine
Journal
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
ISSN: 1749-4486
Titre abrégé: Clin Otolaryngol
Pays: England
ID NLM: 101247023
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
revised:
29
08
2024
received:
15
03
2024
accepted:
09
09
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
aheadofprint
Résumé
To evaluate the effectiveness of nortriptyline regimen and migraine dietary/lifestyle modifications on dizziness and stress levels in patients diagnosed with vestibular migraine (VM). A total of 35 patients diagnosed with definite VM based on the International Classification of Headache Disorders were included in this intervention study. Patients self-selected to receive either nortriptyline regimen alone (10-40 mg daily with biweekly escalation) (group A, n = 17) or migraine dietary/lifestyle modifications alone (group B, n = 18). Main outcome measures were dizziness severity and stress level measured by the visual analog scale (VAS). At 4-week post-treatment, dizziness decreased from 6.0 ± 2.5 to 4.2 ± 3.4 (p = 0.069) in group A and from 8.7 ± 1.5 to 3.6 ± 3.0 (p < 0.001) in group B. VAS for stress changed from 5.5 ± 1.3 to 5.4 ± 2.9 (p = 0.93) and from 6.9 ± 3.2 to 5.0 ± 2.7 (p = 0.025) in groups A and B, respectively. The δ values of the VAS score for dizziness were 1.8 ± 3.7 and 5.1 ± 3.1 and the δ values of the VAS score for stress were 0.06 ± 2.9 and 1.9 ± 3.3 in groups A and B, respectively. Quality of life (QOL) improved in 88% patients in group A and 94% patients in group B. Nortriptyline, at a maximum dose of 40 mg, effectively alleviates patient symptoms, while a migraine diet and lifestyle modifications notably reduce vertiginous symptoms and stress levels in VM patients in 4 weeks. Both interventions are equally effective in ameliorating the QOL of patients. The ideal treatment for patients would likely need to include both medication and diet/lifestyle changes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCRR NIH HHS
ID : TL1TR001415
Pays : United States
Organisme : NCATS NIH HHS
Pays : United States
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
H. K. Neuhauser, “The Epidemiology of Dizziness and Vertigo,” Handbook of Clinical Neurology 137 (2016): 67–82.
S. Weidt, A. B. Bruehl, D. Straumann, S. C. A. Hegemann, G. Krautstrunk, and M. Rufer, “Health‐Related Quality of Life and Emotional Distress in Patients With Dizziness: A Cross‐Sectional Approach to Disentangle Their Relationship,” BMC Health Services Research 14 (2014): 317.
C. Lahmann, P. Henningsen, T. Brandt, et al., “Psychiatric Comorbidity and Psychosocial Impairment Among Patients With Vertigo and Dizziness,” Journal of Neurology, Neurosurgery & Psychiatry 86, no. 3 (2015): 302–308.
R. Burch, P. Rizzoli, and E. Loder, “The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies,” Headache 58, no. 4 (2018): 496–505.
T. Lempert, J. Olesen, J. Furman, et al., “Vestibular Migraine: Diagnostic Criteria (Update),” Journal of Vestibular Research 32, no. 1 (2022): 1–6.
E. J. Formeister, H. G. Rizk, M. A. Kohn, and J. D. Sharon, “The Epidemiology of Vestibular Migraine: A Population‐Based Survey Study,” Otology & Neurotology 39, no. 8 (2018): 1037–1044.
Y. J. Byun, D. A. Levy, S. A. Nguyen, E. Brennan, and H. G. Rizk, “Treatment of Vestibular Migraine: A Systematic Review and Meta‐Analysis,” Laryngoscope 131, no. 1 (2021): 186–194.
M. Maldonado Fernández, J. S. Birdi, G. J. Irving, L. Murdin, I. Kivekäs, and M. Strupp, “Pharmacological Agents for the Prevention of Vestibular Migraine,” Cochrane Database of Systematic Reviews 2015, no. 4 (2015): CD010600, https://doi.org/10.1002/14651858.CD010600.pub2.
M. von Brevern and T. Lempert, “Vestibular Migraine: Treatment and Prognosis,” Seminars in Neurology 40, no. 1 (2020): 83–86.
H. Chu, Y. Wang, X. Ling, K. Li, and X. Yang, “Prophylactic Treatments for Vestibular Migraine: A Systematic Review and Network Meta‐Analysis of Randomized Clinical Trials,” Frontiers in Pharmacology 14 (2023): 1332973.
C. Zhu, Y. Li, Y. Ju, and X. Zhao, “Dizziness Handicap and Anxiety Depression Among Patients With Benign Paroxysmal Positional Vertigo and Vestibular Migraine,” Medicine 99, no. 52 (2020): e23752.
S. Ketola, M. Havia, B. Appelberg, and E. Kentala, “Psychiatric Symptoms in Vertiginous Patients,” Nordic Journal of Psychiatry 69, no. 4 (2015): 287–291.
R Foundation for Statistical Computing, R: A Language and Environment for Statistical Computing. Version 4.2.0 (Vienna, Austria: R Foundation for Statistical Computing, 2022), https://www.R‐project.org/.
A. Kassambara, “rstatix: Pipe‐Friendly Framework for Basic Statistical Tests,” 2021, https://rdrr.io/github/kassambara/rstatix/.
R. A. Roberts, K. E. Watford, E. M. Picou, K. Hatton, T. H. Trone, and E. Y. Brignola, “Effects of Lifestyle Modification on Vestibular Migraine,” Otology & Neurotology 42, no. 10 (2021): e1537–e1543.
L. Kelman, “The Triggers or Precipitants of the Acute Migraine Attack,” Cephalalgia 27, no. 5 (2007): 394–402.
F. C. Rockett, V. R. De Oliveira, K. Castro, M. L. Chaves, A. D. S. Perla, and I. D. Perry, “Dietary Aspects of Migraine Trigger Factors,” Nutrition Reviews 70, no. 6 (2012): 337–356.
C. Sun‐Edelstein and A. Mauskop, “Foods and Supplements in the Management of Migraine Headaches,” Clinical Journal of Pain 25, no. 5 (2009): 446–452.
J. Worm, K. Falkenberg, and J. Olesen, “Histamine and Migraine Revisited: Mechanisms and Possible Drug Targets,” Journal of Headache and Pain 20, no. 1 (2019): 30.
J. M. Borkum, “Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis,” Headache 56, no. 1 (2016): 12–35.
M. Fila, J. Chojnacki, P. Sobczuk, C. Chojnacki, and J. Blasiak, “Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine,” Nutrients 15, no. 2 (2023): 289.
L. Teigen and C. J. Boes, “An Evidence‐Based Review of Oral Magnesium Supplementation in the Preventive Treatment of Migraine,” Cephalalgia 35, no. 10 (2015): 912–922.
K. M. A. Welch and N. M. Ramadan, “Mitochondria, Magnesium and Migraine,” Journal of the Neurological Sciences 134, no. 1–2 (1995): 9–14.
E. Köseoglu, A. Talaslioglu, A. S. Gönül, and M. Kula, “The Effects of Magnesium Prophylaxis in Migraine Without Aura,” Magnesium Research 21, no. 2 (2008): 101–108.
A. Peikert, C. Wilimzig, and R. Köhne‐Volland, “Prophylaxis of Migraine With Oral Magnesium: Results From A Prospective, Multi‐Center, Placebo‐Controlled and Double‐Blind Randomized Study,” Cephalalgia 16, no. 4 (1996): 257–263.
A. Tarighat Esfanjani, R. Mahdavi, M. Ebrahimi Mameghani, M. Talebi, Z. Nikniaz, and A. Safaiyan, “The Effects of Magnesium, l‐Carnitine, and Concurrent Magnesium‐l‐Carnitine Supplementation in Migraine Prophylaxis,” Biological Trace Element Research 150, no. 1–3 (2012): 42–48.
P. S. Sándor, J. Áfra, A. Ambrosini, and J. Schoenen, “Prophylactic Treatment of Migraine With β‐Blockers and Riboflavin: Differential Effects on the Intensity Dependence of Auditory Evoked Cortical Potentials,” Headache 40, no. 1 (2000): 30–35.
J. Schoenen, J. Jacquy, and M. Lenaerts, “Effectiveness of High‐Dose Riboflavin in Migraine Prophylaxis A Randomized Controlled Trial,” Neurology 50, no. 2 (1998): 466–470.
M. C. Salmito, J. A. Duarte, L. O. G. Morganti, et al., “Prophylactic Treatment of Vestibular Migraine,” Brazilian Journal of Otorhinolaryngology 83, no. 4 (2017): 404–410.
E. Domínguez‐Durán, M. A. Montilla‐Ibáñez, M. G. Álvarez‐Morujo De Sande, et al., “Analysis of the Effectiveness of the Prophylaxis of Vestibular Migraine Depending on the Diagnostic Category and the Prescribed Drug,” European Archives of Oto‐Rhino‐Laryngology 277, no. 4 (2020): 1013–1021.
J. R. Dornhoffer, Y. F. Liu, L. Donaldson, and H. G. Rizk, “Factors Implicated in Response to Treatment/Prognosis of Vestibular Migraine,” European Archives of Oto‐Rhino‐Laryngology 278, no. 1 (2021): 57–66.
A. A. Mikulec, F. Faraji, and L. J. Kinsella, “Evaluation of the Efficacy of Caffeine Cessation, Nortriptyline, and Topiramate Therapy in Vestibular Migraine and Complex Dizziness of Unknown Etiology,” American Journal of Otolaryngology 33, no. 1 (2012): 121–127.
M. D. Reploeg and J. A. Goebel, “Migraine‐Associated Dizziness: Patient Characteristics and Management Options,” Otology & Neurotology 23, no. 3 (2002): 364–371.
T. A. Grigol, A. M. Silva, M. M. Ferreira, A. Manso, M. M. Ganança, and H. H. Caovilla, “Dizziness Handicap Inventory and Visual Vertigo Analog Scale in Vestibular Dysfunction,” International Archives of Oto‐Rhino‐Laryngology 20, no. 3 (2016): 241–243.
F. Dutheil, B. Pereira, F. Moustafa, G. Naughton, F. X. Lesage, and C. Lambert, “At‐Risk and Intervention Thresholds of Occupational Stress Using a Visual Analogue Scale,” PLoS One 12, no. 6 (2017): e0178948.